Share Email Print
cover

Proceedings Paper

Phase one clinical trial of the use of focused ultrasound surgery for the treatment of soft-tissue tumors
Author(s): Gail R. ter Haar; Ian H. Rivens; Eleanor Moskovic; Robert Huddart; Andrew G. Visioli
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

A prototype extra-corporeal focused ultrasound surgery device has been built and tested extensively in model systems both in vivo and ex vivo. A phase 1, normal tissue toxicity trial is now underway. Patients with soft tissue tumors lying 4 - 12 cm below the skin surface are being treated using a dose escalation technique. An in situ `ablative intensity' (AI) has been established from preclinical studies. This was found to be 1500 Wcm-2 for up to 3 seconds at 1.7 MHz. Groups of three patients are being treated at doses rising from 25% AI through 50%, 63%, 80%, 100% to 125% AI for 1 second. Finally, 2 and 3 second exposure will be used for the two highest doses. Patients receive no sedation or anaesthetic. Target sites include all soft tissue tumors, especially those of the prostate, kidney and liver. Patients are examined for skin erythema, and are asked to complete pain and symptom questionnaires prior to treatment, immediately after treatment, one week and one month later. Patients receive a diagnostic ultrasound scan before and immediately after exposure, and after 1 week. Those at the highest dose levels are also offered a magnetic resonance scan.

Paper Details

Date Published: 2 April 1998
PDF: 7 pages
Proc. SPIE 3249, Surgical Applications of Energy, (2 April 1998); doi: 10.1117/12.304353
Show Author Affiliations
Gail R. ter Haar, Royal Marsden Hospital (United Kingdom)
Ian H. Rivens, Royal Marsden Hospital (United Kingdom)
Eleanor Moskovic, Royal Marsden Hospital (United Kingdom)
Robert Huddart, Royal Marsden Hospital (United Kingdom)
Andrew G. Visioli, Royal Marsden Hospital (United Kingdom)


Published in SPIE Proceedings Vol. 3249:
Surgical Applications of Energy
Thomas P. Ryan, Editor(s)

© SPIE. Terms of Use
Back to Top